Abiomed To Showcase Advanced Circulatory Support Devices At American College of Cardiology's Annual Scientific Sessions

DANVERS, Mass. and ATLANTA, March 8 /PRNewswire-FirstCall/ -- ABIOMED, Inc. , a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart, today announced the showcase of its AB5000(TM) Circulatory Support System at the American College of Cardiology's (ACC) 55th Annual Scientific Session. ACC is the premier cardiovascular medical meeting, bringing together more than 30,000 cardiologists to further breakthroughs in cardiovascular medicine. ABIOMED will occupy booth #3870 at the ACC Conference which is being held at the Georgia World Congress Center in Atlanta from March 11-14.

ABIOMED is a sponsor of the Texas Heart Institute's educational session on March 11 at 08:30 a.m. at the Atlanta Marriott Marquis. This session entitled, "The Cardiologist's New Frontier: Mechanical Support For Heart Failure," will include in-depth presentations on ABIOMED's AB5000(TM) Circulatory Support System, BVS(R) 5000 Biventricular Support System, as well as the IMPELLA(R) RECOVER(R) minimally invasive cardiovascular support systems which are available in Europe under CE Mark approval but are not yet available in the United States. ACC attendees interested in attending this session should contact Gail Farnan at 954-684-9234 or gfarnan@abiomed.com.

"ABIOMED's advanced medical technologies provide patients in acute heart failure with FDA-approved circulatory support for all potentially recoverable indications. For cardiac surgeons and cardiologists alike, this temporary support can potentially help their patients avoid a heart transplant," said Michael R. Minogue, Chairman, President and Chief Executive Officer of ABIOMED.

To date, more than 8,000 patients worldwide have been supported with these devices. Patients who have recovered included those suffering from cardiogenic shock resulting from myocardial infarction, myocarditis, postpartum cardiomyopathy, ventricular septal defect, refractory arrhythmias, failed heart transplants, right ventricular assistance with implantable LVAD (Left Ventricular Assist Device), and post-cardiotomy cardiogenic shock (PCCS). ABIOMED's devices encourage recovery and are easier to implant, utilizing cannulae inserted through a small incision, rather than more traumatic bridge-to-transplant devices that core the ventricles and require heart-lung machines for implantation. The ABIOMED(R) AB5000(TM) System also allows patients to walk with the support of the console, which helps recovery.

ABOUT ABIOMED

Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced "AB'-EE-O-MED") is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. ABIOMED currently manufactures and sells the AB5000(TM) Circulatory Support System and the BVS(R) 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. In Europe, ABIOMED offers the IMPELLA(R) RECOVER(R) minimally invasive cardiovascular support systems under CE Mark approval. The IMPELLA products are not yet available for sale in the United States. The Company's AbioCor(R) Implantable Replacement Heart was the subject of an initial clinical trial under an Investigational Device Exemption from the United States Food and Drug Administration. The AbioCor has not been approved for commercial distribution, and is not available for use or sale outside of the initial clinical trial. For additional information please visit: http://www.abiomed.com.

Contacts: Liza Heapes Daniel Sutherby ABIOMED, INC. ABIOMED, INC. Media Relations Chief Financial Officer 978-646-1668 978-646-1812 mediarelations@abiomed.comir@abiomed.com FORWARD-LOOKING STATEMENTS

This Release contains forward-looking statements, including statements regarding development of ABIOMED's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward- looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.

CONTACT: Liza Heapes, Media Relations, +1-978-646-1668,mediarelations@abiomed.com, or Daniel Sutherby, Chief Financial Officer,+1-978-646-1812, ir@abiomed.com, both of ABIOMED, INC.

Web site: http://www.abiomed.com//